Aptevo Therapeutics, Inc. (APVO)
1.61
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
1.57
-0.04
(-2.48%)
After-Hours: 20:00
Aptevo Therapeutics Enterprise Value : -3.303M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -3.303M |
| October 22, 2026 | -3.303M |
| October 21, 2026 | -3.318M |
| October 20, 2026 | -3.296M |
| October 19, 2026 | -3.318M |
| October 16, 2026 | -3.289M |
| October 15, 2026 | -3.176M |
| October 14, 2026 | -3.133M |
| October 13, 2026 | -3.133M |
| October 12, 2026 | -2.982M |
| October 09, 2026 | -3.048M |
| October 08, 2026 | -3.034M |
| October 07, 2026 | -2.977M |
| October 06, 2026 | -3.041M |
| October 05, 2026 | -3.034M |
| October 02, 2026 | -3.091M |
| October 01, 2026 | -3.091M |
| September 30, 2026 | -3.005M |
| September 29, 2026 | -2.949M |
| September 28, 2026 | -2.878M |
| September 25, 2026 | -2.906M |
| September 24, 2026 | -2.991M |
| September 23, 2026 | -2.906M |
| September 22, 2026 | -2.963M |
| September 21, 2026 | -3.020M |
| Date | Value |
|---|---|
| September 18, 2026 | -2.977M |
| September 17, 2026 | -2.977M |
| September 16, 2026 | -3.147M |
| September 15, 2026 | -3.162M |
| September 14, 2026 | -3.034M |
| September 11, 2026 | -3.005M |
| September 10, 2026 | -2.991M |
| September 09, 2026 | -2.970M |
| September 08, 2026 | -2.920M |
| September 04, 2026 | -3.119M |
| September 03, 2026 | -3.162M |
| September 02, 2026 | -1.899M |
| September 01, 2026 | -2.268M |
| August 31, 2026 | -2.126M |
| August 28, 2026 | -2.232M |
| August 27, 2026 | -2.154M |
| August 26, 2026 | -2.168M |
| August 25, 2026 | -2.097M |
| August 24, 2026 | -2.168M |
| August 21, 2026 | -1.785M |
| August 20, 2026 | -1.672M |
| August 19, 2026 | -1.714M |
| August 18, 2026 | -1.473M |
| August 17, 2026 | -1.601M |
| August 14, 2026 | -1.416M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.356M |
| Total Expenses (Quarterly) | 6.356M |
| EPS Diluted (Quarterly) | -5.313 |
| Earnings Yield | -3.59K% |
| Normalized Earnings Yield | -3587.75 |